Endo Inc.
Endo Inc., a prominent player in the pharmaceutical and medical device industry, is headquartered in the United States. Founded in 1997, the company has established itself as a leader in pain management, urology, and other therapeutic areas, with a strong operational presence across North America and Europe. Endo Inc. is renowned for its innovative products, including advanced pain relief medications and minimally invasive surgical devices, which are designed to improve patient outcomes. The company’s commitment to quality and efficacy has earned it a significant market position, marked by notable achievements in research and development. With a focus on addressing unmet medical needs, Endo Inc. continues to drive advancements in healthcare, making a meaningful impact on patients' lives.
DitchCarbon Score
How does Endo Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Endo Inc.'s score of 15 is higher than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Endo Inc.'s reported carbon emissions
In 2023, Endo Inc. reported total carbon emissions of approximately 59,050,000 kg CO2e, comprising about 13,435,000 kg CO2e from Scope 1 and about 45,570,000 kg CO2e from Scope 2 emissions. This marks a slight increase in emissions compared to 2022, where the total was approximately 48,260,000 kg CO2e, with Scope 1 at about 12,718,000 kg CO2e and Scope 2 at about 36,208,000 kg CO2e. Over the past few years, Endo has demonstrated a trend of reducing its emissions. In 2021, the company reported approximately 60,390,000 kg CO2e, with Scope 1 emissions at about 16,872,000 kg CO2e and Scope 2 at about 43,967,000 kg CO2e. This indicates a reduction in total emissions from 2021 to 2022, but a subsequent increase in 2023. Endo Inc. has not disclosed any specific reduction targets or initiatives as part of its climate commitments. The company continues to focus on its operational emissions, primarily through Scope 1 and Scope 2, while no data is available regarding Scope 3 emissions. As a company headquartered in the US, Endo is part of a broader industry context that increasingly prioritises sustainability and carbon footprint reduction.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 27,475,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 37,395,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Endo Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
